Glenmark Pharmaceuticals wins USFDA approval for Ciclopirox cream
Drug manufacturer Glenmark Pharmaceuticals has announced that USFDA has granted authorization for selling and distribution of Ciclopirox cream in the US market.
The company has obtained approval for Ciclopirox cream in the strength of 0.77%. The approved product is the generic version of Loprox cream marketed by Medicis.
Ciclopirox Cream is prescribed for treating fungal as well as yeast infections of the skin, such as athlete`s foot, jock itch, and ringworm.
During the 12-month period ended September 2009, the product has generated sales of USD 8 million.
Shares of the company declined Rs 0.15, or 0.07%, to settle at Rs 222.20. The total volume of shares traded was 74,016 on Bombay Stock Exchange (BSE) (Friday).






